The Pharmaceutical Research and Manufacturers of America (PhRMA) represents many of the world’s leading innovative biopharmaceutical research companies. Its executive director for the Middle East and Africa, Samir Khalil, discusses the need for a value-based pricing system in Saudi Arabia, the country’s successful COVID-19 response and how the Vision 2030 initiative is helping bring more investment. In addition, he explains why countries in the region should focus less on manufacturing and more on the big opportunity presented by biopharma companies: research and development.
A pro-innovation policy environment will bring access to new medicines and encourage investment in Saudi Arabia while reducing barriers for companies to expand and thrive in the market
